{Reference Type}: Clinical Trial, Phase II
{Title}: Melanoma neoantigen vaccines: Are we getting more personal now?
{Author}: Latifyan S;Haanen JB;
{Journal}: Med
{Volume}: 5
{Issue}: 4
{Year}: 2024 Apr 12
暂无{DOI}: 10.1016/j.medj.2024.03.004
{Abstract}: KEYNOTE-9421 is a randomized phase II adjuvant study in patients with resected stage III melanoma investigating a personalized neoantigen mRNA vaccine in combination with anti-PD-1. The study gave a clear signal of superiority for the vaccine plus anti-PD-1 in relapse-free and distant-metastasis-free survival but is not yet conclusive, and important questions remain.